Speakers

Chris Simon was appointed CEO May 2016. Previously, he served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. He brings more than 20 years of experience helping businesses transform and grow.

Mr. Simon was the lead partner for the strategy review with Haemonetics that launched in October 2015, where he gained invaluable insights into the company’s business and markets. Together with management and the Board of Directors, he co-architected the strategic plan that the company is now implementing.

He was with McKinsey since 1993. Before that he served in commercial and operating roles at Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion. Mr. Simon currently serves on the Board of Directors of AdvaMed.

Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.

James D'Arecca joined Haemonetics as Chief Financial Officer in April 2022 and is responsible for the Company’s global finance organization, including investor relations. He previously served as Chief Financial Officer of TherapeuticsMD, a women's healthcare company. Prior to this role, Mr. D'Arecca was Senior Vice President and Chief Accounting Officer at Allergan plc for nearly seven years until its merger with AbbVie, Inc. in May 2020, and earlier in his career he held finance and business development positions at Bausch + Lomb, Merck & Co., Inc., and Schering-Plough. Mr. D'Arecca began his career with PricewaterhouseCoopers, where he had an industry focus on pharmaceuticals, medical devices, and consumer products. He holds a Bachelor of Science in Accounting from Rutgers University and a Master of Business Administration from Columbia University.

Anila Lingamneni joined Haemonetics in April 2020 as Executive Vice President, Chief Technology Officer. She oversees the Company’s Innovation Agenda and leads research, development, software and medical and clinical affairs.

Previously, Ms. Lingamneni was Vice President, Renal R&D at Baxter International, where she was responsible for the product portfolio delivering renal therapy solutions to dialysis patients, including devices, software, disposables and fluids. While there, she drove a globally distributed team of engineers and scientists to drive long-term product roadmap definition and therapy innovation and delivered critical launches. Before joining Baxter, Ms. Lingamneni held several roles at General Electric Healthcare, including Chief Technology Officer of the X-Ray Diagnostic Imaging Business Unit, where she led a global engineering function, rebalanced portfolio investments to drive value and managed expansion into emerging markets.

Ms. Lingamneni received a Bachelor of Science in Electrical and Electronics Engineering and a Master of Science in Mathematics from Birla Institute of Technology and Science in India. She also earned a Master of Science in Biomedical Engineering from Iowa State University. Ms. Lingamneni has received numerous awards, including the Healthcare Businesswomen's Association Outstanding Luminary Award and the Society of Women Engineers Women of the Year Award, and has authored numerous publications.

Stewart W. Strong joined Haemonetics in September 2019 as President, Global Hospital. He is responsible for overseeing the global Hospital business to drive market leadership and accelerate profitable growth.

With more than 20 years of experience in Interventional cardiology and radiology, general and cardiac surgery and vascular access procedures, Mr. Strong has a robust background developing and leading high performance teams across multiple functions in the medical device space.

Prior to joining Haemonetics, Mr. Strong was President and General Manager of the Interventional Business Unit for Teleflex Incorporated. While in this role, Mr. Strong helped to transform Teleflex into an established brand in the Interventional Cardiology space. Notably, Mr. Strong helped lead the successful $1 billion acquisition and integration of Vascular Solutions, Inc. in 2017 and the acquisition of Essential Medical in 2018. He previously held the role of Global Vice President and General Manager of Teleflex Cardiac Care and Vice President of Sales for their Vascular business unit. Mr. Strong joined Teleflex through the acquisition of Vidacare Corporation where he held the position of Vice President of Sales. Additionally, he has held leadership roles of increasing responsibility at AtriCure, Inc., Medtronic’s Heart Valve division and Johnson & Johnson’s Ethicon Endo-Surgery division.

Mr. Strong is a graduate of the University of Connecticut.

Jake Bonner is Haemonetics’ Vice President North America, Plasma & Blood Center, leading the Sales and Operations, Product Application, Training, and Field Service Teams in this market. He has been with Haemonetics since 2017, serving in roles including Vice President, Plasma and Blood Center, and Senior Director, Plasma Business Development.

Mr. Bonner has more than 25 years of experience in the Medical Technology industry and B2B sales and leadership, successfully launching and growing new and disruptive technologies. As Regional Business Manager at AngioDynamics, he was responsible for sales and clinical personnel delivering a portfolio of products across Interventional Radiology, Interventional Cardiology, Vascular Surgery, Electrophysiology, and Cardiothoracic Surgery markets. At Navilyst Medical, formerly Boston Scientific Oncology, he served as Regional Business and Sales Manager for Vascular Access and Fluid Management Product Lines for the Midwestern United States.

Mr. Bonner graduated with a Bachelor of Science in Business Administration from The Ohio State University.

Thomas Lenzen serves as Haemonetics’ Vice President International/OUS, Global Plasma & Blood Center. In this role, Mr. Lenzen leads the commercial teams for both of these businesses in EMEA (Europe, Middle East, Africa), APAC (Asia Pacific), and Japan. In addition, he has responsibility for the field service and technical support teams in these regions. He is also the Site Leader for Haemonetics’ EMEA headquarters in Signy, Switzerland. Mr. Lenzen joined Haemonetics in January 2015, and has served as Vice President, Sales, Europe; and Vice President, Plasma International.

Mr. Lenzen has more than 25 years of international experience in healthcare and medical technologies, creating and launching products and expanding into new markets and geographies. His experience prior to Haemonetics includes European and Global Leadership roles with Bausch & Lomb, and serving as Principal with A.T. Kearney in Munich and Boston.

Mr. Lenzen earned a Bachelor of Arts in Economics from University Bamberg in Germany, and an MBA and PhD at University St. Gallen in Switzerland. He also participated in the Advanced Management Program at Harvard Business School.

Olga Guyette leads global investor relations and treasury functions for Haemonetics. She joined Haemonetics in February 2016 and prior to her current role served as a finance partner to the President of the Global Blood Center business. Before joining Haemonetics, Ms. Guyette’s background includes roles in accounting, corporate finance, and equity research at Alere, Inc. and Virtua Research. Ms. Guyette earned a Bachelor of Arts in Business Administration with a concentration in Banking and Investments from American University-Central Asia and a Master of Science degree in Finance from Suffolk University.